COMPANY PROFILE

Aro Biotherapeutics

Explore full profile

Focused on the development of a new protein drug platform

Philadelphia, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2023

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Aro Biotherapeutics

Aro Biotherapeutics is pioneering a novel protein drug platform known as Centyrins, aimed at improving the efficacy and safety of treatments for cancer and other serious diseases. Centyrins are engineered to target multiple cell surface receptors simultaneously, allowing for the delivery of complex drug payloads to specific cell types and tissues. This approach promises to unlock new therapeutic mechanisms and offer better outcomes for patients. The company primarily serves the biotechnology and pharmaceutical sectors, focusing on clients involved in cancer research and treatment. Operating in the highly specialized market of biotherapeutics, Aro Biotherapeutics employs a business model centered around research and development, partnering with other biotech firms and healthcare providers to bring their innovative solutions to market. Revenue is generated through collaborations, licensing agreements, and potential future sales of Centyrin-based therapies.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Philadelphia, United States
Employees: 51
Open positions: 1
Dealroom signal: 71.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Aro Biotherapeutics.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Nov 2023	$42M	$440M	BVF Partners · Johnson & Johnson Innovation · Northpond Ventures · HealthCap	↗
SERIES BOther financing	Jan 2023	$24M	$440M	Cowen Group	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Aro Biotherapeutics website traffic

Latest recorded traffic for Aro Biotherapeutics is 2.2K monthly website visits, down 24.1% over the last three months. Aro Biotherapeutics's team declined 3.8% over the past year.

Latest monthly visits2.2K 3-month web change-24.1% 1-year team growth-3.8%

Monthly website visitsMar 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational	19	$60M	$240M
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational
BTBAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations	Kingston, United States	Closed
ITInterline TherapeuticsLeveraging advances in genomics, proteomics, and computational chemistry to identify new medicines	San Francisco, United States	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational
EBEisbach BioInnovative start-up in biotechnology developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes	Planegg, Germany	Operational
CACatalymDeveloping innovative immunotherapies to transform cancer patients’ lives by effectively engaging their own immune systems to combat this malignant disease	Munich, Germany	Operational